How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/apatinib-capecitabine-oxaliplatin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Apatinib Capecitabine Oxaliplatin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Apatinib Capecitabine Oxaliplatin (Apatinib Capecitabine Oxaliplatin) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Tyrosine kinase inhibitor + chemotherapy combination. Area: Oncology.

phase 3 Tyrosine kinase inhibitor + chemotherapy combination VEGFR-2 (apatinib); thymidylate synthase (capecitabine); DNA (oxaliplatin) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Apatinib Capecitabine Oxaliplatin (Apatinib Capecitabine Oxaliplatin) — Hebei Medical University. This combination uses apatinib to inhibit vascular endothelial growth factor receptor (VEGFR) signaling while capecitabine and oxaliplatin provide chemotherapy to target cancer cells.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Apatinib Capecitabine Oxaliplatin TARGET	Apatinib Capecitabine Oxaliplatin	Hebei Medical University	phase 3	Tyrosine kinase inhibitor + chemotherapy combination	VEGFR-2 (apatinib); thymidylate synthase (capecitabine); DNA (oxaliplatin)
Chemotherapy + Imatinib	Chemotherapy + Imatinib	Gruppo Italiano Malattie EMatologiche dell'Adulto	phase 3	Tyrosine kinase inhibitor + chemotherapy combination	BCR-ABL, c-KIT, PDGFR

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Tyrosine kinase inhibitor + chemotherapy combination class)

Gruppo Italiano Malattie EMatologiche dell'Adulto · 1 drug in this class
Hebei Medical University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Apatinib Capecitabine Oxaliplatin — Competitive Intelligence Brief. https://druglandscape.com/ci/apatinib-capecitabine-oxaliplatin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab